Passage Bio is a fully integrated genetic medicines company based in Philadelphia, PA that is developing a portfolio of five life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company was founded by industry veterans Stephen Squinto, Ph.D. and Tachi Yamada, M.D. in a partnership with gene therapy pioneer James Wilson, M.D., Ph.D. The company has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program as well as the Penn Orphan Disease Center.